Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Net Cash Flow: 2021-2025

Historic Net Cash Flow for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Sep 2025 value amounting to $166.5 million.

  • Amylyx Pharmaceuticals' Net Cash Flow rose 6325.65% to $166.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $152.4 million, marking a year-over-year increase of 341.90%. This contributed to the annual value of -$91.6 million for FY2024, which is 185.24% down from last year.
  • According to the latest figures from Q3 2025, Amylyx Pharmaceuticals' Net Cash Flow is $166.5 million, which was up 7,385.51% from -$2.3 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Net Cash Flow registered a high of $166.5 million during Q3 2025, and its lowest value of -$112.4 million during Q3 2023.
  • Its 3-year average for Net Cash Flow is $14.7 million, with a median of $461,000 in 2024.
  • The largest annual percentage gain for Amylyx Pharmaceuticals' Net Cash Flow in the last 5 years was 6,325.65% (2025), contrasted with its biggest fall of 3,965.73% (2025).
  • Over the past 5 years, Amylyx Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$26.5 million in 2021, then slumped by 72.54% to -$45.7 million in 2022, then spiked by 175.92% to $34.7 million in 2023, then plummeted by 82.48% to $6.1 million in 2024, then surged by 6,325.65% to $166.5 million in 2025.
  • Its last three reported values are $166.5 million in Q3 2025, -$2.3 million for Q2 2025, and -$17.8 million during Q1 2025.